

NephFlo

.....

The World's FIRST Artificial, Implantable Kidney

Scope of the Problem



Option 1: Transplants (Preferred Option)

Critically Limited Supply

- US: Only 22k performed in 2020
- Waitlist = ~ 4 years
- >10% Reject Rate
- Lifelong medication required

12-13 people die daily waiting.

Option 2: Dialysis ('Backup' Option)

Transitional, Expensive, Inconvenient

- Only temporary treatment
 - Antiquated technology •
- 50% mortality without kidney replacement
 - \$90k per patient annually to Medicare •

Transitional solution, at best.

The remaining ~33% of kidney patients either haven't qualified for treatment yet, or in other countries may never receive it.



Kidney Failure Market Size



Market size will increase 5% / annum due to aging population, increasing incidence of diabetes and hypertension.

3

Core Technology



Advanced Nanotube filtration technology



Novel chemical separation method



More efficient than standard dialysis



Patented Technology



Highly Scalable



One Core Technology Solving Both Problems



All product versions vastly improve quality of life and liveability, and dramatically reduce costs. WE SAVE LIVES!

5

Competitive Advantage

Artificial Implantable Kidney	Wearable kidney	Desktop kidney	
Unlimited	Unlimited	Unlimited	
Higher efficacy + eliminates rejection	Increases survivability + liveability	Increases survivability + liveability	
Large cost savings: \$443k → \$200k	Large cost savings: \$90k / year → \$50k 1x	Large cost savings: \$90k / year → \$50k 1x	
Zero waitlist	Done at home and/or on-the-go; Zero hospital visits	Used in hospital or home	
	Artificial Implantable Kidney Unlimited Higher efficacy + eliminates rejection Large cost savings: \$443k → \$200k Zero waitlist	Artificial Implantable KidneyWearable kidneyUnlimitedUnlimitedHigher efficacy + eliminates rejectionIncreases survivability + liveabilityLarge cost savings: \$443k → \$200kLarge cost savings: \$90k / year → \$50k 1xZero waitlistDone at home and/or on-the-go; Zero hospital visits Treatment time 240 mins → 30-90 mins	

NephFlo owns Patents across both its Implantable + External Products. NephFlo's product suite dramatically reduces TCO, and, Transforms mostly Inpatient Care to Outpatient/Home Care

6

Competitive Landscape

	Qidni	Kidney Project	US Kidney	Dialysis	Transplant	Xenograft	NephFlo
Implantable	X	×	×	X	\checkmark	\checkmark	√
Wearable	X	×	X	\checkmark	X	×	\checkmark
Non Biological	\checkmark	×	\checkmark	X	X	X	√
Cost Saving	X	×	X	X	X	X	√
No Needed Dialysis	\checkmark	\checkmark	\checkmark	X	\checkmark	\checkmark	√
No Needed Reoperation	X	×	X	X	×	X	√
Customizable lon Selection	X	×	X	X	X	X	\checkmark
Ideal for CHF patients	X	X	×	X	X	X	

Business Model

Main Revenue Stream

\$200k Implantable Kidneys



Wearable or Tabletop Kidney

Additional Revenue Streams

+

(+) Device Sales

Implantable,

Wearable, and

Desktop Kidneys

Disposables

Disposable waste receptacles for external Kidneys

Perform Implantation

specialists and nurses.

surgeries, train transplant

+

Surgery Centers Reimburg

+

Reimbursement (HMOs)

Device, Implantation, Follow-up care

Data Monetization

+

Treatment results and other valuable data

Go-To Market Perfect procedure Train & orient specialists Negotiate Reimbursement Get FDA approvals a. Release Wearable b. Release Implantable



The Team



Saul Orbach

CEO

Serial Entrepreneur, VC, Business Education, Advisor, Start-ups and successful exits



Vladimir Rassushin CTO

Nanotech Product Developer, Technology and Science Project Management, Entrepreneur



Dr. Stuart Greenstein Chief Medical Officer

Kidney Transplant Specialist, Westchester Medical Center, NY



Dr. Noa Lachman-Senesh R&D Team lead

Department of Materials Science and Engineering

The Advisory Board

Medical	Medical	Carbon Nanotubes	Reimbursement	Medical Device Industry Advisor	Regulatory	US Clinical Trial Coordinator
Dr. Samuel Saltzberg	Dr. Karl Skorecki	Prof. Daniel Nessim	Andrew Thorrens	Alan Kholos	Janice Hogan	Tina Kholos
Kidney Care, Transplant Care, Rush University	Leading Nephrologist, Kidney Care Specialist, Rambam Hospital	Bar Ilan University, Laboratory for the synthesis of innovative nanostructures.	Imprimis Rx	BD Biosciences	Hogan Lovells	

Investment Opportunity

Seed Round	A Round
Amount: \$2.6M Time: 18 Months	Amount: \$5M Time: 24 Months
Purpose/Use • IP Development • Key Personnel • Prototype Development	Purpose/Use3 path productization• Regulatory preparation• Develop Specialist training program• Plan surgical/medical centers
Outcome/ Quantifiable Results • Working Prototype • Clinical Trials for Wearable kidney	Outcome/ Quantifiable Results • Clinical Trials for implantable Kidney • 1st Medical Research Center • Initial wearable device sales

Your capital helps us further NephFlo's Mission to save Millions of Lives!



CKD is a death sentence for most people who get it!



NephFlo is disrupting the treatment landscape for kidney failure.



NephFlo offers the first artificial implantable kidney and both wearable and tabletop artificial kidneys.



Current transplant wait list is ~4 years. 12-13 people die every day in the US waiting!



NephFlo expects to *market* its wearable kidney within 3 years.

With NephFlo, no one has to die waiting for a transplant!

NephFlo

The World's FIRST Artificial, Implantable Kidney

Contact Us

Saul Orbach

+1 917 795 2582; +972-54-6273213

saulo@nephflo.com

www.nephflo.com